MUC4 and MUC5AC are highly specific tumour-associated mucins in biliary tract cancer

British Journal of Cancer

Volumn 98, Issue 10, 2008, Pages 1675-1681

  Matull, W R ^a   Andreola, F ^a   Loh, A ^b   Adiguzel, Z ^a   Deheragoda, M ^c   Qureshi, U ^a   Batra, S K ^d   Swallow, D M ^b   Pereira, S P ^a,c  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Biliary tract cancer; Cholangiocarcinoma; Mucin glycoprotein; Tumour marker

Indexed keywords

MESSENGER RNA; MUCIN 4; MUCIN 5AC; TUMOR MARKER;

ADULT; AGED; ARTICLE; BILE; BILE DUCT OBSTRUCTION; BILIARY TRACT CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HEPATOBILIARY SYSTEM; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN DETERMINATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEROLOGY; SERUM; SURVIVAL; UPREGULATION; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; BILE; BILIARY TRACT NEOPLASMS; BLOTTING, WESTERN; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MUCINS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 43649106488     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604364     Document Type: Article

References (33)

1. American Joint Committee on Cancer (AJCC) (2002) AJCC Cancer Staging Manual. Springer: New York
2. Argüeso P, Balaram M, Spurr-Michaud S, Keutmann HT, Dana MR, Gipson IK (2002) Decreased levels of the goblet cell mucin MUC5AC in tears of patients with Sjögren syndrome. Invest Ophthalmol Vis Sci 43: 1004-1011
3. Bamrungphon W, Prempracha N, Bunchu N, Rangdaeng S, Sandhu T, Srisukho S, Boonla C, Wongkham S (2007) A new mucin antibody/enzyme-linked lectin-sandwich assay of serum MUC5AC mucin for the diagnosis of cholangiocarcinoma. Cancer Lett 247: 301-308
4. Boonla C, Wongkham S, Sheehan JK, Wongkham C, Bhudhisawasdi V, Tepsiri N, Pairojkul C (2003) Prognostic value of serum MUC5AC mucin in patients with cholangiocarcinoma. Cancer 98: 1438-1443
5. Carlstedt I, Sheehan JK, Corfield AP, Gallagher JT (1985) Mucous glycoproteins: a gel of a problem. Essays Biochem 20: 40-76
6. Carraway KL, Ramsauer VP, Haq B, Carothers Carraway CA (2003) Cell signaling through membrane mucins. BioEssays 25: 66-71
7. Funes M, Miller JK, Lai C, Carraway III KL, Sweeney C (2006) The mucin Muc4 potentiates neuregulin signaling by increasing the cell-surface populations of ErbB2 and ErbB3. J Biol Chem 281: 19310-19319
8. Hollingsworth MA, Swanson BJ (2004) Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 4: 45-60
9. Hovenberg HW, Davies JR, Carlstedt I (1996) Different mucins are produced by the surface epithelium and the submucosa in human trachea: identification of MUC5AC as a major mucin from the goblet cells. Biochem J 318: 319-324
10. Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz J, Youssef M, Klimstra D, Blumgart LH (2001) Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 234: 507-517
11. Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WMC, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Thursz MR, Wasan H (2002) Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 51(Suppl VI): i1-i9
12. Lee KT, Liu TS (2001) Altered mucin gene expression in stone-containing intrahepatic bile ducts and cholangiocarcinomas. Dig Dis Sci 46: 2166-2172
13. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408
14. Malhi H, Gores GJ (2006) Review article: the modern diagnosis and therapy of cholangiocarcinoma. Aliment Pharmacol Ther 23: 1287-1296
15. Moniaux N, Andrianifahanana M, Brand RE, Batra SK (2004a) Multiple roles of mucins in pancreatic cancer, a lethal and challenging malignancy. Br J Cancer 91: 1633-1638
16. Moniaux N, Chaturvedi P, Varshney GC, Meza JL, Rodriguez-Sierra JF, Aubert J-P, Batra SK (2007) Human MUC4 mucin induces ultrastructural changes and tumorigenicity in pancreatic cancer cells. Br J Cancer 97: 345-357
17. Moniaux N, Escande F, Batra SK, Porchet N, Laine A, Aubert JP (2000) Alternative splicing generates a family of putative secreted and membrane-associated MUC4 mucins. Eur J Biochem 267: 4536-4544
18. Moniaux N, Varshney GC, Chauhan SC, Copin MC, Jain M, Wittel UA, Andrianifahanana M, Aubert JP, Batra SK (2004b) Generation and characterization of anti-MUC4 monoclonal antibodies reactive with normal and cancer cells in humans. J Histochem Cytochem 52: 253-261
19. Nehls O, Gregor M, Klump B (2004) Serum and bile markers for cholangiocarcinoma. Semin Liver Dis 24: 139-154
20. Nollet S, Forgue-Lafitte ME, Kirkham P, Bara J (2002) Mapping of two new epitopes on the apomucin encoded by MUC5AC gene: expression in normal GI tract and colon tumors. Int J Cancer 99: 336-343
21. Pino V, Ramsauer VP, Salas P, Carothers Carraway CA, Carraway KL (2006) Membrane mucin Muc4 induces density-dependent changes in ERK activation in mammary epithelial and tumor cells: role in reversal of contact inhibition. J Biol Chem 281: 29411-29420
22. Rousseau K, Wickstrom C, Whitehouse DB, Carlstedt I, Swallow DM (2003) New monoclonal antibodies to non-glycosylated domains of the secreted mucins MUC5B and MUC7. Hybrid Hybridomics 22: 293-299
23. Saitou M, Goto M, Horinouchi M, Tamada S, Nagata K, Hamada T, Osako M, Takao S, Batra SK, Aikou T, Imai K, Yonezawa S (2005) MUC4 expression is a novel prognostic factor in patients with invasive ductal carcinoma of the pancreas. J Clin Pathol 58: 845-852
24. Seyama Y, Makuuchi M (2007) Current surgical treatment for bile duct cancer. World J Gastroenterol 13: 1505-1515
25. Shibahara H, Tamada S, Higashi M, Goto M, Batra SK, Hollingsworth MA, Imai K, Yonezawa S (2004) MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma-mass forming type. Hepatology 39: 220-229
26. Singh AP, Chaturvedi P, Batra SK (2007) Emerging roles of MUC4 in cancer: a novel target for diagnosis and therapy. Cancer Res 67: 433-436
27. Singh AP, Moniaux N, Chauhan SC, Meza JL, Batra SK (2004) Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis. Cancer Res 64: 622-630
28. Swartz MJ, Batra SK, Varshney GC, Hollingsworth MA, Yeo CJ, Cameron JL, Wilentz RE, Hruban RH, Argani P (2002) MUC4 expression increases progressively in pancreatic intraepithelial neoplasia. Am J Clin Pathol 117: 791-796
29. Tamada S, Shibahara H, Higashi M, Goto M, Batra SK, Imai K, Yonezawa S (2006) MUC4 is a novel prognostic factor of extrahepatic bile duct carcinoma. Clin Cancer Res 12: 4257-4264
30. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726
31. Wongkham S, Sheehan JK, Boonla C, Patrakitkomjorn S, Howard M, Kirkham S, Sripa B, Wongkham C, Bhudhisawasdi V (2003) Serum MUC5AC mucin as a potential marker for cholangiocarcinoma. Cancer Lett 195: 93-99
32. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137
33. Zhang J, Perez A, Yasin M, Soto P, Rong M, Theodoropoulos G, Carothers Carraway CA, Carraway KL (2005) Presence of MUC4 in human milk and at the luminal surfaces of blood vessels. J Cell Physiol 204: 166-177